| Host: |
Mouse |
| Applications: |
FC/IF/IHC |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Mouse monoclonal antibody anti-CD16 is suitable for use in Flow Cytometry, Immunofluorescence and Immunohistochemistry research applications. |
| Clonality: |
Monoclonal |
| Clone ID: |
CB16 |
| Conjugation: |
Unconjugated |
| Isotype: |
IgMk |
| Formulation: |
PBS with 0.02% Sodium Azide. |
| Purification: |
Affinity purified from tissue culture. |
| Concentration: |
Can be provided as 100 µg/mL, 500 µg/mL or 1mg/mL. |
| Dilution Range: |
Flow cytometry (0, 5-1, 0 µg/million cells in 0, 1 ml). Immunofluorescence (0, 5-1, 0 µg/ml). Immunohistology (1-2 µg/ml for 30 min at RT; an appropriate antigen retrieval method for staining of formalin-fixed tissues has not been established to date |
| Storage Instruction: |
Store for up to 1 year at 2-8°C upon receipt. |
| Gene Symbol: |
FCGR3A |
| Gene ID: |
2214 |
| Uniprot ID: |
FCG3A_HUMAN |
| Immunogen: |
A BALB/c mouse was immunized with human PBL. Fusion partner: NS-1. |
| Tissue Specificity | Expressed in natural killer cells (at protein level). Expressed in a subset of circulating monocytes (at protein level). |
| Post Translational Modifications | Glycosylated. Contains high mannose- and complex-type oligosaccharides. Glycosylation at Asn-180 is mandatory for high affinity binding to the Fc and for discrimination between fucosylated and afucosylated IgG glycoforms. Undergoes rapid ectodomain shedding upon NK cell stimulation. The soluble form is produced by a proteolytic cleavage mediated by ADAM17. Repeated stimulation causes receptor shedding, a mechanism that allows for increased NK cell motility and detachment from opsonized target cells while avoiding activation-induced NK cell apoptosis. Phosphorylated at RSSTR motif by PKC. The relevant physiological PKCs might be PRKCI, PRKCG, PRKCE, PRKCH and PRKCQ. |
| Function | Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger. Mediates IgG effector functions on natural killer (NK) cells. Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation. Involved in the generation of memory-like adaptive NK cells capable to produce high amounts of IFNG and to efficiently eliminate virus-infected cells via ADCC. Regulates NK cell survival and proliferation, in particular by preventing NK cell progenitor apoptosis. Fc-binding subunit that associates with CD247 and/or FCER1G adapters to form functional signaling complexes. Following the engagement of antigen-IgG complexes, triggers phosphorylation of immunoreceptor tyrosine-based activation motif (ITAM)-containing adapters with subsequent activation of phosphatidylinositol 3-kinase signaling and sustained elevation of intracellular calcium that ultimately drive NK cell activation. The ITAM-dependent signaling coupled to receptor phosphorylation by PKC mediates robust intracellular calcium flux that leads to production of pro-inflammatory cytokines, whereas in the absence of receptor phosphorylation it mainly activates phosphatidylinositol 3-kinase signaling leading to cell degranulation. Costimulates NK cells and trigger lysis of target cells independently of IgG binding. Mediates the antitumor activities of therapeutic antibodies. Upon ligation on monocytes triggers TNFA-dependent ADCC of IgG-coated tumor cells. Mediates enhanced ADCC in response to afucosylated IgGs. (Microbial infection) Involved in Dengue virus pathogenesis via antibody-dependent enhancement (ADE) mechanism. Secondary infection with Dengue virus triggers elevated levels of afucosylated non-neutralizing IgG1s with reactivity to viral envelope/E protein. Viral antigen-IgG1 complexes bind with high affinity to FCGR3A, facilitating virus entry in myeloid cells and subsequent viral replication. |
| Protein Name | Low Affinity Immunoglobulin Gamma Fc Region Receptor Iii-AIgg Fc Receptor Iii-ACd16-IiCd16a AntigenFc-Gamma Riii-AlphaFc-Gamma RiiiFc-Gamma RiiiaFcriiiFcriiiaFcgammariiiaFcr-10Igg Fc Receptor Iii-2Cd Antigen Cd16a |
| Database Links | Reactome: R-HSA-198933Reactome: R-HSA-2029481Reactome: R-HSA-2029482Reactome: R-HSA-2029485Reactome: R-HSA-9664323Reactome: R-HSA-9664422 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinSecretedExists Also As A Soluble Receptor |
| Alternative Antibody Names | Anti-Low Affinity Immunoglobulin Gamma Fc Region Receptor Iii-A antibodyAnti-Igg Fc Receptor Iii-A antibodyAnti-Cd16-Ii antibodyAnti-Cd16a Antigen antibodyAnti-Fc-Gamma Riii-Alpha antibodyAnti-Fc-Gamma Riii antibodyAnti-Fc-Gamma Riiia antibodyAnti-Fcriii antibodyAnti-Fcriiia antibodyAnti-Fcgammariiia antibodyAnti-Fcr-10 antibodyAnti-Igg Fc Receptor Iii-2 antibodyAnti-Cd Antigen Cd16a antibodyAnti-FCGR3A antibodyAnti-CD16A antibodyAnti-FCG3 antibodyAnti-FCGR3 antibodyAnti-IGFR3 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
![Anti-CD16 antibody [LNK16] (STJ16100960)](https://cdn11.bigcommerce.com/s-zso2xnchw9/images/stencil/300x300/products/149677/346901/STJ16100960_1__63931.1681999080.jpg?c=1 "Anti-CD16 antibody [LNK16] (STJ16100960)")
![Anti-CD16 antibody [2H7] (STJ16101699)](https://cdn11.bigcommerce.com/s-zso2xnchw9/images/stencil/300x300/products/152205/347057/STJ16101699_1__20887.1681999316.jpg?c=1 "Anti-CD16 antibody [2H7] (STJ16101699)")